Zobrazeno 1 - 10
of 74
pro vyhledávání: '"Masahiro Sakagami"'
Autor:
Jayne E. Hastedt, Per Bäckman, Andrew R. Clark, William Doub, Anthony Hickey, Guenther Hochhaus, Phil J. Kuehl, Claus-Michael Lehr, Peter Mauser, Jason McConville, Ralph Niven, Masahiro Sakagami, Jeffry G. Weers
Publikováno v:
AAPS Open, Vol 2, Iss 1, Pp 1-1 (2016)
Externí odkaz:
https://doaj.org/article/6e5951894e0a4f65983b1feb9e14ab9c
Publikováno v:
Biopharmaceutics & Drug Disposition. 41:32-43
The kinetic clarification of lung disposition for inhaled drugs in humans via pharmacokinetic (PK) modeling aids in their development and regulation for systemic and local delivery, but remains challenging due to its multiplex nature. This study exer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b12f8a02f99d17baa1bf43e54378068
https://doi.org/10.1002/bdd.2210
https://doi.org/10.1002/bdd.2210
Autor:
Donald F. Brophy, Rami A. Al-Horani, Masahiro Sakagami, Elsamani I. Abdelfadiel, Erika J. Martin, Daniel K. Afosah, Bassem M. Mohammed, Shravan Morla, Umesh R. Desai, Jyothi C. Sistla
Publikováno v:
J Thromb Haemost
Background Human factor XIa (FXIa) is an actively pursued target for development of safer anticoagulants. Our long-standing hypothesis has been that allosterism originating from heparin-binding site(s) on coagulation enzymes is a promising approach t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f011456ef4503dfc3f7422b82d5f88e
https://doi.org/10.1111/jth.14606
https://doi.org/10.1111/jth.14606
Publikováno v:
Pulmonary Pharmacology & Therapeutics. 53:52-60
Emphysema progressively destroys alveolar structures, leading to disability and death, yet remains irreversible and incurable to date. Impaired vascular endothelial growth factor (VEGF) signaling is an emerging pathogenic mechanism, thereby proposing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4dfc94a66a1855390fdbd1ad211c7007
https://doi.org/10.1016/j.pupt.2018.09.002
https://doi.org/10.1016/j.pupt.2018.09.002
Autor:
Masahiro Sakagami
Publikováno v:
Advanced drug delivery reviews.
The assessment and prediction of lung absorption and disposition are an increasingly essential preclinical task for successful discovery and product development of inhaled drugs for both local and systemic delivery. Hence, in vitro, ex vivo and in vi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bc7f66a866212e8ce958853c3363bae
https://pubmed.ncbi.nlm.nih.gov/32763274
https://pubmed.ncbi.nlm.nih.gov/32763274
Autor:
Masahiro Sakagami, Ruba S. Darweesh
Publikováno v:
European Journal of Pharmaceutical Sciences. 115:68-76
As a promising long-acting inhaled formulation, liposomal ciprofloxacin (Lipo-CPFX) was characterized in the in vitro human lung epithelial Calu-3 cell monolayer system, compared to ciprofloxacin in solution (CPFX). Its modulated absorptive transport
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0da8a4ac2057b7334452a9167588b83
https://doi.org/10.1016/j.ejps.2018.01.018
https://doi.org/10.1016/j.ejps.2018.01.018
In Vivo-Relevant Transwell Dish-Based Dissolution Testing for Orally Inhaled Corticosteroid Products
Publikováno v:
Pharmaceutical Research. 36
To establish an in vivo-relevant Transwell dish-based dissolution test system for the “respirable” aerosols of inhaled corticosteroids (ICSs) using marketed inhaler products. “Respirable” ≤ 5.8 or 6.5 μm aerosols of 7 ICSs from 11 inhaler
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43621488f6ed8c2e04ae3ac680826344
https://doi.org/10.1007/s11095-019-2635-2
https://doi.org/10.1007/s11095-019-2635-2
Autor:
Connor P. O'Hara, Daniel K. Afosah, Masahiro Sakagami, Bhaumik B. Patel, Umesh R. Desai, Shravan Morla, Rio S. Boothello
Publikováno v:
The FASEB Journal. 33
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dccea7a7308df12a5d4296475d622314
https://doi.org/10.1096/fasebj.2019.33.1_supplement.782.17
https://doi.org/10.1096/fasebj.2019.33.1_supplement.782.17
Autor:
Masahiro Sakagami, Matthew S. Halquist, Priya P Nadkarni, Richard M. Costanzo, H. Thomas Karnes
Publikováno v:
Therapeutic Delivery. 6:297-306
Background: Oxyntomodulin (OXM1–37) is an anorectic gut-secreting peptide with a promise to treat obesity, but its needle-free delivery has yet to be successful. Results: Pulmonary delivery of OXM1–37, but not its C-terminal octapeptides, caused
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd8bcc08fdb08184daff4485177c57af
https://doi.org/10.4155/tde.14.117
https://doi.org/10.4155/tde.14.117
Autor:
Masahiro Sakagami, Harm Jan Bogaard, Peter R. Byron, Norbert F. Voelkel, Shiro Mizuno, Jose Gomez-Arroyo, Donatas Kraskauskas, Antonio Abbate, Benjamin W. Van Tassell, Laszlo Farkas, Aamer Syed
Publikováno v:
Gomez-Arroyo, J, Sakagami, M, Syed, A A, Farkas, L, Van Tassell, B, Kraskauskas, D, Mizuno, S, Abbate, A, Bogaard, H J, Byron, P R & Voelkel, N F 2015, ' Iloprost reverses established fibrosis in experimental right ventricular failure ', European Respiratory Journal, vol. 45, no. 2, pp. 449-462 . https://doi.org/10.1183/09031936.00188013
European Respiratory Journal, 45(2), 449-462. European Respiratory Society
European Respiratory Journal, 45(2), 449-462. European Respiratory Society
Prostacyclin and its analogues improve cardiac output and functional capacity in patients with pulmonary arterial hypertension (PAH); however, the underlying mechanism is not fully understood. We hypothesised that prostanoids have load-independent be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52bea64f23891d7024fa70daa37f584b
https://doi.org/10.1183/09031936.00188013
https://doi.org/10.1183/09031936.00188013